

REMARKS

In response to the Examiner's telephone message on March 8, 2006, the Applicants are submitting this Second Supplemental Amendment. The Examiner requested an amendment to the Abstract. Applicants believe that the attached amendment will be satisfactory to the Examiner. The Applicants are canceling the compound of formula (I) from the Abstract and adding a generalized chemical name for the compounds to the Abstract.


No new matter is being introduced by these amendments. No fee is required.

The Applicants believe that all claims are in a condition for allowance and respectfully request that the Examiner issue the pending claims. If the Examiner disagrees, the Applicants request the Examiner to contact the undersigned to discuss the claims with the goal of agreeing on allowable subject matter.

The Commissioner is authorized to deduct any other fee necessary to keep this application pending, from Deposit Account 19-0134.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922


David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: March 10, 2006